Article
Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.
Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2012
Minde Zeng, Yimin Mao, Guangbi Yao, JinLin Hou, Hao Wang, Hong Ren, Yuming Wang, Xiaqiu Zhou, Daozhen Xu, Yagang Chen, Junqi Niu, Youming Chen, Yaozong Wang, Dixon Jonathan, Barker Keith
Abstract excerpt
BACKGROUND: Adefovir dipivoxil (ADV) is a nucleotide analogue with proven efficacy in chronic hepatitis B (CHB). AIMS: This study investigated long-term ADV treatment in HBeAg-positive patients. METHODS: A total of 480 Chinese subjects with HBeAg-positive CHB who participated in a 1-year, double-blind, placebo-controlled study of ADV 10 mg daily were offered open-label continuation for a further 208 weeks....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.